Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSwedish Orphan Regulatory News (0MTD)

Share Price Information for Swedish Orphan (0MTD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 154.65
Bid: 151.45
Ask: 157.85
Change: 1.025 (0.67%)
Spread: 6.40 (4.23%)
Open: 154.775
High: 154.775
Low: 151.15
Yest. Close: 153.625
0MTD Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.
Date   Source Headline
4th May 20167:00 amRNSSwedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares
27th Apr 20166:45 amRNSSobi publishes 2015 Annual Report
22nd Apr 20167:00 amRNSSobi signs licensing agreement with Affibody for IL-1
24th Mar 20167:01 amRNSEuropean Commission approves transfer of marketing authorisation for Elocta® to Sobi
29th Feb 20167:02 amRNSSobi updates outlook for 2016
26th Feb 20167:01 amRNSSobi publishes its report for the fourth quarter and full year 2015
23rd Feb 20167:00 amRNSSobi to initiate clinical development programs in acute gout and Still's disease, and receives US patent on new formulation for Kineret® (anakinra)
28th Jan 20167:00 amRNSSobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleeding rates with long-term Elocta® treatment
11th Jan 20167:00 amRNSSobi(TM) announces commercial launch of Elocta® in first countries in Europe
7th Jan 20167:00 amRNSSobi gains commercial rights for Relistor®, Deflux® and Solesta® from PharmaSwiss
22nd Dec 20157:00 amRNSSobi receives orphan drug designation for Alprolix® in Switzerland
21st Dec 20157:01 amRNSLars Dreiøe joins Sobi as Senior Vice President, Chief Quality & Compliance Officer
24th Nov 20157:01 amRNSSobi and Biogen's Elocta® (rFVIIIFc) approved in Europe for the treatment of haemophilia A
16th Oct 20157:00 amRNSXiapex® approved for the treatment of Peyronie's disease in Switzerland
30th Sep 20157:00 amRNSNew number of shares and votes in Swedish Orphan Biovitrum AB (publ)
29th Sep 20157:01 amRNSSobi CEO invests in 2015 LTI programme and divests a portion of incentive shares
11th Sep 20157:31 amRNSSwedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
10th Sep 20157:00 amRNSFDA validates Orfadin® oral suspension filing
8th Sep 20157:00 amRNSSobi opens European and Benelux office in Brussels
4th Sep 20157:00 amRNSSobi celebrates 25 years with Orfadin® (nitisinone) - a result of ground-breaking Swedish research
18th Aug 20159:01 amRNSResults from B-YOND study reinforce long-term clinical profile of Alprolix for the treatment of haemophilia B
16th Jul 20157:01 amRNSSobi publishes its Report for the Second Quarter 2015 - raises guidance
16th Jul 20157:00 amRNSSobi exercises opt-in right for Alprolix®
30th Jun 20153:16 pmRNSResolutions from Sobi's Annual General Meeting
27th May 20157:02 amRNSNotice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
15th Apr 201512:01 pmRNSSwedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
30th Mar 20157:01 amRNSNotice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
27th Feb 201512:06 pmRNSBiogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix® paediatric study
12th Feb 20157:00 amRNSInvitation - Presentation of Sobi's fourth quarter and full year results 2014
19th Dec 20147:00 amRNSSobi's 2011 Long-Term incentive Programme meets all objectives
9th Dec 20141:15 pmRNSSobi CEO Geoffrey McDonough sells a portion of 2014 incentive shares
30th Oct 20147:01 amRNSSobi publishes Report for the Third Quarter 2014
9th Oct 20148:01 pmRNSSobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe
18th Jul 20148:01 amRNSSobi's board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive program
18th Jul 20147:01 amRNSSobi publishes Report for the Second Quarter 2014
1st Jul 20148:30 amRNSSobi awarded Company of the Year at the European Mediscience Awards 2014
9th Jun 20147:02 amRNSThe US Food and Drug Administration (FDA) approves Eloctate(TM)
5th Jun 20147:01 amRNSSobi Establishes North American Office in Massachusetts
26th May 20142:31 pmRNSSwedish Orphan Biovitrum AB (publ): Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Operations
12th May 20147:18 amRNSBiogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
8th May 20145:31 pmRNSSwedish Orphan Biovitrum AB (publ): Annette Clancy joins Sobi's Board of Directors
8th May 20149:41 amRNSSobi publishes Report for the First Quarter 2014
16th Apr 20147:01 amRNSSobi publishes Annual Report 2013
10th Apr 201412:05 pmRNSBiogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A
7th Apr 20147:01 amRNSSobi becomes market authorisation holder for Xiapex in Europe
25th Mar 201411:01 amRNSCometriq® approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Login to your account

Don't have an account? Click here to register.